Thyroid Eye Disease
- PMID: 36556449
- PMCID: PMC9787503
- DOI: 10.3390/life12122084
Thyroid Eye Disease
Abstract
Thyroid eye disease (TED), an autoimmune inflammatory disorder of the orbit, presents with a potential array of clinical sequelae. The pathophysiology behind TED has been partially characterized in the literature. There remain certain elusive mechanisms welcoming of research advances. Disease presentation can vary, but those that follow a characteristic course start mild and increase in severity before plateauing into an inactive phase. Diagnosis and evaluation include careful physical examination, targeted laboratory work up, appropriate imaging studies, and tailored treatment regimens. Special consideration may apply to certain populations, such as pediatric and pregnant patients.
Keywords: Grave’s disease; Hashimoto’s thyroiditis; chronic lymphocytic thyroiditis; euthyroid eye disease; exophthalmos; orbital inflammation; proptosis; teprotumumab; thyroid eye disease; thyroid-associated orbitopathy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures







Similar articles
-
Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.Cureus. 2023 Aug 21;15(8):e43878. doi: 10.7759/cureus.43878. eCollection 2023 Aug. Cureus. 2023. PMID: 37746376 Free PMC article. Review.
-
Severe thyroid-associated orbitopathy in Hashimoto's thyroiditis. Report of 2 cases.Endocr J. 2011;58(5):343-8. doi: 10.1507/endocrj.k11e-019. Epub 2011 Mar 17. Endocr J. 2011. PMID: 21427503
-
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Clinical Trial.
-
Early experience with teprotumumab for chronic thyroid eye disease.Am J Ophthalmol Case Rep. 2020 May 15;19:100744. doi: 10.1016/j.ajoc.2020.100744. eCollection 2020 Sep. Am J Ophthalmol Case Rep. 2020. PMID: 32462101 Free PMC article.
-
[Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].Endokrynol Pol. 2011;62 Suppl 1:1-7. Endokrynol Pol. 2011. PMID: 22125104 Review. Polish.
Cited by
-
Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.Cureus. 2023 Aug 21;15(8):e43878. doi: 10.7759/cureus.43878. eCollection 2023 Aug. Cureus. 2023. PMID: 37746376 Free PMC article. Review.
-
The role of IL-6 in thyroid eye disease: an update on emerging treatments.Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025. Front Ophthalmol (Lausanne). 2025. PMID: 40297767 Free PMC article. Review.
-
Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database.Clin Endocrinol (Oxf). 2025 Apr;102(4):482-489. doi: 10.1111/cen.15183. Epub 2024 Dec 17. Clin Endocrinol (Oxf). 2025. PMID: 39690929 Free PMC article.
-
Teprotumumab for Thyroid Eye Disease: Mechanism, Clinical Efficacy, and Current Challenges.Antibodies (Basel). 2025 Jun 30;14(3):55. doi: 10.3390/antib14030055. Antibodies (Basel). 2025. PMID: 40700295 Free PMC article. Review.
-
Optical coherence tomography angiography in thyroid associated ophthalmopathy: a systematic review.BMC Ophthalmol. 2024 Jul 22;24(1):304. doi: 10.1186/s12886-024-03569-5. BMC Ophthalmol. 2024. PMID: 39039451 Free PMC article.
References
-
- Stan M.N. Natural History, Risk Factors, and Management of Patients with Mild GO. In: Bahn R.S., editor. Graves’ Disease—A Comprehensive Guide for Clinicians. Springer Science+Business Media; New York, NY, USA: 2015. pp. 241–255.
Publication types
LinkOut - more resources
Full Text Sources